Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (AFACET)

Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer

This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.

Study Overview

• Status: Completed
• Conditions: Carcinoma, Non-Small-Cell Lung
• Intervention / Treatment: Drug: Cetuximab; Drug: Afatinib

• Study Type: Interventional
• Enrollment (Actual): 37
• Phase: Phase 2

Contacts and Locations

Study Locations

• Netherlands
  • Amsterdam, Netherlands, 1007 MB
    • VU Medical Center
  • Groningen, Netherlands, 9713 GZ
    • University Medical Center Groningen
  • Maastricht, Netherlands, 6229 HX
    • Maastricht UMC+
  • North-Holland
    • Amsterdam, North-Holland, Netherlands, 1066 CX
      • Antoni van Leeuwenhoek

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Pathologically or cytologically confirmed stage IV non-small cell lung cancer, harboring an EGFR exon 20 insertion mutation.
• 18 years or older at time of study entry.
• Life expectancy of at least three months.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix 1).
• Measurable disease, according to RECIST 1.1.
• At baseline adequate fresh or archived tissue from a histological biopsy or a cellblock obtained by fine needle aspiration of a tumor lesion that is not radiated prior to biopsy, must be available. Baseline tissue samples must have been obtained after the last line of systemic therapy prior to study entry.
• Adequate normal organ and marrow function as defined below:
• Absolute leukocyte count ≥ 3 x 109/L (> 3000 per mm3)
• Platelet count ≥ 75 x 109/L (>75,000 per mm3)
• Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤ 5x upper limit of normal (ULN).
• Serum creatinine clearance >30 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance.
• Women of child-bearing potential: these subjects must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use highly effective contraception, as defined in section 5.2.2, from 7 days prior to enrollment, throughout the treatment period and for seven months after completion of the treatment with cetuximab.
• Males must agree to take appropriate precautions to avoid fathering a child from the first dose of study treatment through 3 months after the final administration of investigational drugs.
• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
• Ability to give written informed consent before patient registration.

Exclusion Criteria:

• Participation in another clinical study with an investigational product during the last 2 weeks.
• Prior treatment with EGFR targeting antibodies (prior treatment with EGFR TKI's is allowed).
• Other active malignancy.
• History of hypersensitivity to afatinib or cetuximab.
• Major surgery (excluding diagnostic procedures e.g. mediastinoscopy or video assisted thoracic surgery (VATS) biopsy) within 28 days of the start of study treatment.
• Radiotherapy less than two weeks prior to the start of study treatment.
• Symptomatic brain metastases.
• Breast feeding is not allowed during study treatment.
• Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, myocardial infarction within 12 months prior to the study entry, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety and anti-tumor activity of the test drugs.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Afatinib plus cetuximab; Afatinib, 40 mg once daily, orally. Cetuximab, 500 mg/m² intravenously, every 2 weeks. Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs.	Drug: Cetuximab; Injection; Drug: Afatinib; Tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease control rate after 18 weeks	To determine the disease control rate at 18 weeks of afatinib and cetuximab treatment in patients with NSCLC harboring an EGFR exon 20 insertion mutation.	18 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective tumor response	Objective tumor response (complete response and partial response)determined by RECIST v1.1.	Scans every 6 weeks until tumor progression, start of another treatment or death.
Safety (intensity and incidence of adverse events)	Safety as indicated by intensity and incidence of adverse events, graded according to NCI CTCAE Version 4.03.	Up to 30 days after last study drug intake.
Duration of response (DOR)	Time from documentation of tumor response to disease progression	Scans every 6 weeks until tumor progression
Progression free survival	Time from the date of start treatment to the date of the first documented tumor progression as determined by RECIST1.1, or death due to any cause	Until progression, every 6 weeks up to progression
Overall survival	Time form date of start treatment to the date of death from any cause	Every 6 weeks up to death

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Genetic profiling to assess predictors of response and resistance - circulating free (cf)DNA	cfDNA samples will be collected to assess predictors of response and resistance.	At baseline, cycle 1 day 15 and at treatment discontinuation (expected 6 months after start)

Collaborators and Investigators

• Sponsor: The Netherlands Cancer Institute
• Collaborators: Boehringer Ingelheim; Merck Serono International SA
• Investigators: Principal Investigator: J de Langen, MD, PhD, NKI-AVL

Study record dates

Study Major Dates

• Study Start (Actual): December 4, 2018
• Primary Completion (Actual): September 6, 2022
• Study Completion (Actual): September 6, 2022

Study Registration Dates

• First Submitted: September 3, 2018
• First Submitted That Met QC Criteria: October 31, 2018
• First Posted (Actual): November 1, 2018

Study Record Updates

• Last Update Posted (Actual): October 18, 2023
• Last Update Submitted That Met QC Criteria: October 17, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Immunological; Protein Kinase Inhibitors; Cetuximab; Afatinib
• Other Study ID Numbers: M18ACX

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No